VKORC1 pharmacogenomics summary.
作者信息
Owen Ryan P, Gong Li, Sagreiya Hersh, Klein Teri E, Altman Russ B
机构信息
Department of Genetics, Stanford University, Stanford, California 94305-5120, USA.
出版信息
Pharmacogenet Genomics. 2010 Oct;20(10):642-4. doi: 10.1097/FPC.0b013e32833433b6.
Abstract
摘要
相似文献
1
VKORC1 pharmacogenomics summary.维生素K环氧化物还原酶复合体亚单位1（VKORC1）药物基因组学概述。
Pharmacogenet Genomics. 2010 Oct;20(10):642-4. doi: 10.1097/FPC.0b013e32833433b6.
2
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.华法林剂量以及细胞色素P450 2C9（CYP2C9）和维生素K环氧化物还原酶复合体亚单位1（VKORC1）的药物基因组学——原理与展望
Thromb Res. 2007;120(1):1-10. doi: 10.1016/j.thromres.2006.10.021. Epub 2006 Dec 11.
3
Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.通过第二代智能扩增流程对细胞色素P450（CYP2C9）和维生素K环氧化物还原酶（VKORC1）基因进行快速单核苷酸多态性检测以调整华法林剂量
Clin Chem. 2009 Apr;55(4):804-12. doi: 10.1373/clinchem.2008.115295. Epub 2009 Jan 30.
4
Vitamin K epoxide reductase complex subunit 1 (VKORC1 ) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study.维生素K环氧化物还原酶复合体亚单位1（VKORC1）基因多态性影响维生素K摄入后的抗凝反应：一项初步研究。
J Thromb Haemost. 2008 Jul;6(7):1226-8. doi: 10.1111/j.1538-7836.2008.03003.x. Epub 2008 Jul 1.
5
Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose.维生素K环氧化物还原酶复合体1（VKORC1）、细胞色素P450 2C9（CYP2C9）及国际标准化比值（INR）反应对华法林稳定剂量的相对贡献
Blood. 2009 Apr 23;113(17):4125-6. doi: 10.1182/blood-2009-01-200600.
6
A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance.一名维生素K拮抗剂抵抗患者的维生素K环氧化物还原酶复合体亚基1（VKORC1）突变
J Thromb Haemost. 2005 Jul;3(7):1533-5. doi: 10.1111/j.1538-7836.2005.01449.x.
7
Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.VKORC1 多态性比 CYP2C9 多态性对早期华法林国际标准化比值的控制和出血率的影响更大。
Br J Haematol. 2012 Jul;158(2):256-261. doi: 10.1111/j.1365-2141.2012.09150.x. Epub 2012 May 10.
8
Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.香港华裔患者群体中维生素K环氧化物还原酶复合体1（VKORC1）变体与华法林剂量的关联
Pharmacogenet Genomics. 2005 Oct;15(10):687-91. doi: 10.1097/01.fpc.0000174789.77614.68.
9
[Vitamin K epoxide reductase complex 1 gene polymorphism and warfarin dose requirement in Chinese patients].[中国患者维生素K环氧化物还原酶复合体1基因多态性与华法林剂量需求]
Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Jul;35(7):652-4.
10
The pharmacogenomics of warfarin (Coumadin) administration.
Conn Med. 2006 Apr;70(4):251-2.
引用本文的文献
1
Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects.VKORC1-1639G>A 和 rs397509427 在华法林治疗患者和健康叙利亚受试者中的频率。
Cardiovasc Ther. 2023 Nov 23;2023:8898922. doi: 10.1155/2023/8898922. eCollection 2023.
2
Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants.优化携带 CYP2C9*13 变异的汉族华法林患者的剂量算法。
Eur J Clin Pharmacol. 2023 Oct;79(10):1315-1320. doi: 10.1007/s00228-023-03540-1. Epub 2023 Jul 17.
3
The role of , and 1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study.1639 变体及其他因素在上消化道出血易感性中的作用：一项全病例对照研究。
J Pharm Pharm Sci. 2023 Jan 30;26:11136. doi: 10.3389/jpps.2023.11136. eCollection 2023.
4
Hyper-responsiveness to warfarin in a young patient with the VKORC1 -1639GA/CYP2C9*1*46 genotype: a case report.一名携带VKORC1 -1639G>A/CYP2C9*1/*46基因型的年轻患者对华法林超敏反应：一例报告
Thromb J. 2022 Oct 27;20(1):65. doi: 10.1186/s12959-022-00425-8.
5
Identifying signatures of natural selection in Indian populations.鉴定印度人群中的自然选择特征。
PLoS One. 2022 Aug 4;17(8):e0271767. doi: 10.1371/journal.pone.0271767. eCollection 2022.
6
A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in , , , , , , and Genes.一种用于同时分析、、、、、、和基因中17种临床相关基因多态性的稳健且快速/多重药物遗传学检测方法。
Pharmaceuticals (Basel). 2022 May 22;15(5):637. doi: 10.3390/ph15050637.
7
Pharmacogenomic landscape of Indian population using whole genomes.利用全基因组分析印度人群的药物基因组学图谱。
Clin Transl Sci. 2022 Apr;15(4):866-877. doi: 10.1111/cts.13153. Epub 2022 Mar 26.
8
Identification of intrinsically disorder regions in non-structural proteins of SARS-CoV-2: New insights into drug and vaccine resistance.鉴定 SARS-CoV-2 非结构蛋白中的无规则区域：对药物和疫苗耐药性的新认识。
Mol Cell Biochem. 2022 May;477(5):1607-1619. doi: 10.1007/s11010-022-04393-5. Epub 2022 Feb 24.
9
Pharmacogenomic analysis of a genetically distinct Indigenous population.遗传独特的原住民人群的药物基因组学分析。
Pharmacogenomics J. 2022 Mar;22(2):100-108. doi: 10.1038/s41397-021-00262-4. Epub 2021 Nov 25.
10
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.使用DMET™平台对韩国人群中重要药物代谢基因进行综合分析。
Transl Clin Pharmacol. 2021 Sep;29(3):135-149. doi: 10.12793/tcp.2021.29.e14. Epub 2021 Sep 2.
本文引用的文献
1
The largest prospective warfarin-treated cohort supports genetic forecasting.规模最大的接受华法林治疗的前瞻性队列研究支持基因预测。
Blood. 2009 Jan 22;113(4):784-92. doi: 10.1182/blood-2008-04-149070. Epub 2008 Jun 23.
2
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.一项针对对华法林维持剂量有重大影响的常见基因变异的全基因组扫描。
Blood. 2008 Aug 15;112(4):1022-7. doi: 10.1182/blood-2008-01-134247. Epub 2008 Jun 5.
3
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.利用药物遗传学和临床因素预测华法林的治疗剂量。
Clin Pharmacol Ther. 2008 Sep;84(3):326-31. doi: 10.1038/clpt.2008.10. Epub 2008 Feb 27.
4
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.基于CYP2C9和VKORC1基因分型的华法林剂量需求前瞻性研究。
Clin Pharmacol Ther. 2008 Jul;84(1):83-9. doi: 10.1038/sj.clpt.6100453. Epub 2008 Jan 9.
5
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.华法林的药物遗传学：监管、科学及临床问题
J Thromb Thrombolysis. 2008 Feb;25(1):45-51. doi: 10.1007/s11239-007-0104-y. Epub 2007 Oct 1.
6
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.华法林剂量以及细胞色素P450 2C9（CYP2C9）和维生素K环氧化物还原酶复合体亚单位1（VKORC1）的药物基因组学——原理与展望
Thromb Res. 2007;120(1):1-10. doi: 10.1016/j.thromres.2006.10.021. Epub 2006 Dec 11.
7
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.编码维生素K环氧化物还原酶复合体亚单位1（VKORC1）Asp36Tyr多态性易导致对华法林耐药。
Blood. 2007 Mar 15;109(6):2477-80. doi: 10.1182/blood-2006-08-038984. Epub 2006 Nov 16.
8
A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme.
J Thromb Haemost. 2007 Jan;5(1):191-3. doi: 10.1111/j.1538-7836.2006.02261.x. Epub 2006 Oct 12.
9
Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.评估当前用于华法林过度抗凝逆转的维生素K给药算法：需要更个性化的给药方案。
Eur J Haematol. 2006 Dec;77(6):457-62. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2957.x. Epub 2006 Oct 17.
10
Pharmacogenetics of warfarin: current status and future challenges.华法林的药物遗传学：现状与未来挑战。
Pharmacogenomics J. 2007 Apr;7(2):99-111. doi: 10.1038/sj.tpj.6500417. Epub 2006 Sep 19.
Zotero 插件